<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04930809</url>
  </required_header>
  <id_info>
    <org_study_id>VER-PK-001</org_study_id>
    <nct_id>NCT04930809</nct_id>
  </id_info>
  <brief_title>Single and Multiple Dose Study of VER-01 in Healthy Volunteers</brief_title>
  <official_title>Open-label Study to Evaluate the Pharmacokinetics and Safety of VER-01after Single and Multiple Administration of Different Doses to Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vertanical GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vertanical GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of pharmacokinetics, tolerability and safety of VER-01 in healthy volunteers&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Determination of the single and multiple dose pharmacokinetic profile of VER-01 in healthy&#xD;
      volunteers.&#xD;
&#xD;
      Single dose: 6 subjects each will receive VER-01 corresponding to 2.5 mg (Group A), 5 mg&#xD;
      (Group B), 10 mg (Group C) or 20 mg THC (Group D) in the morning.&#xD;
&#xD;
      Multiple dose: 6 Subjects each receive VER-01 corresponding to 5 mg (Group E) or 10 mg (Group&#xD;
      F) THC in the morning and in the evening on 4 consecutive days. A third group (Group G)&#xD;
      receives VER-01 corresponding to 12.5 mg THC in the morning and 20 mg THC in the evening on 4&#xD;
      consecutive days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic profile of Δ9-tetrahydrocannabinol [THC] - AUC 0-t</measure>
    <time_frame>Group A-D: Day 1; Group E-G: Day 1 and 4</time_frame>
    <description>Analysis of the AUC 0-t (AUC from time 0 to 24 hours) of THC over a defined period of time.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic profile of Δ9-tetrahydrocannabinol [THC] - AUC 0-∞</measure>
    <time_frame>Group A-D: Day 1; Group E-G: Day 1 and 4</time_frame>
    <description>Analysis of AUC 0-∞ (AUC from time 0 extrapolated to infinity) of THC over a defined period of time.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic profile of Δ9-tetrahydrocannabinol [THC] - C max</measure>
    <time_frame>Group A-D: Day 1; Group E-G: Day 1 and 4</time_frame>
    <description>Analysis of C max (maximum plasma concentration) of THC over a defined period of time.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile of Δ9-tetrahydrocannabinol [THC], 11-Hydroxy-Δ9-tetrahydrocannabinol [11-OH-THC] and 11-Nor-9-carboxy-Δ9-tetrahydrocannabinol [THC-COOH] - AUC 0-t</measure>
    <time_frame>Group A-D: Day 1; Group E-G: Day 1 and 4</time_frame>
    <description>Analysis of AUC 0-t (AUC from time 0 to 24 hours) of 11-OH-THC and THC-COOH over a defined period of time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile of Δ9-tetrahydrocannabinol [THC], 11-Hydroxy-Δ9-tetrahydrocannabinol [11-OH-THC] and 11-Nor-9-carboxy-Δ9-tetrahydrocannabinol [THC-COOH] - AUC 0-∞</measure>
    <time_frame>Group A-D: Day 1; Group E-G: Day 1 and 4</time_frame>
    <description>Analysis of AUC 0-∞ (AUC from time 0 extrapolated to infinity) of 11-OH-THC and THC-COOH over a defined period of time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile of Δ9-tetrahydrocannabinol [THC], 11-Hydroxy-Δ9-tetrahydrocannabinol [11-OH-THC] and 11-Nor-9-carboxy-Δ9-tetrahydrocannabinol [THC-COOH] - C max</measure>
    <time_frame>Group A-D: Day 1; Group E-G: Day 1 and 4</time_frame>
    <description>Analysis of C max (maximum plasma concentration) of 11-OH-THC and THC-COOH over a defined period of time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile of Δ9-tetrahydrocannabinol [THC], 11-Hydroxy-Δ9-tetrahydrocannabinol [11-OH-THC] and 11-Nor-9-carboxy-Δ9-tetrahydrocannabinol [THC-COOH] - λ z</measure>
    <time_frame>Group A-D: Day 1; Group E-G: Day 1 and 4</time_frame>
    <description>Analysis of λ z (terminal elimination constant) of THC, 11-OH-THC and THC-COOH over a defined period of time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile of Δ9-tetrahydrocannabinol [THC], 11-Hydroxy-Δ9-tetrahydrocannabinol [11-OH-THC] and 11-Nor-9-carboxy-Δ9-tetrahydrocannabinol [THC-COOH] - t 1/2</measure>
    <time_frame>Group A-D: Day 1; Group E-G: Day 1 and 4</time_frame>
    <description>Analysis of t 1/2 (elimination half-life) of THC, 11-OH-THC and THC-COOH over a defined period of time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile of Δ9-tetrahydrocannabinol [THC], 11-Hydroxy-Δ9-tetrahydrocannabinol [11-OH-THC] and 11-Nor-9-carboxy-Δ9-tetrahydrocannabinol [THC-COOH] - T max</measure>
    <time_frame>Group A-D: Day 1; Group E-G: Day 1 and 4</time_frame>
    <description>Analysis of T max (time to reach Cmax) of THC, 11-OH-THC and THC-COOH over a defined period of time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile of Δ9-tetrahydrocannabinol [THC], 11-Hydroxy-Δ9-tetrahydrocannabinol [11-OH-THC] and 11-Nor-9-carboxy-Δ9-tetrahydrocannabinol [THC-COOH] - C L/F</measure>
    <time_frame>Group A-D: Day 1; Group E-G: Day 1 and 4</time_frame>
    <description>Analysis of C L/F (plasma clearance) the pharmacokinetic profile of THC, 11-OH-THC and THC-COOH over a defined period of time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile of Δ9-tetrahydrocannabinol [THC], 11-Hydroxy-Δ9-tetrahydrocannabinol [11-OH-THC] and 11-Nor-9-carboxy-Δ9-tetrahydrocannabinol [THC-COOH] - V area/F</measure>
    <time_frame>Group A-D: Day 1; Group E-G: Day 1 and 4</time_frame>
    <description>Analysis of V area/F (volume of distribution) of THC, 11-OH-THC and THC-COOH over a defined period of time.</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>VER-01 single dose (2.5 mg THC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PK profile is investigated after oral intake of a single dose VER-01 corresponding to 2.5 mg THC (Group A).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VER-01 single dose (5 mg THC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PK profile is investigated after oral intake of a single dose VER-01 corresponding to 5 mg THC (Group B).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VER-01 single dose (10 mg THC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PK profile is investigated after oral intake of a single dose VER-01 corresponding to 10 mg THC (Group C).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VER-01 single dose (20 mg THC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PK profile is investigated after oral intake of a single dose VER-01 corresponding to 20 mg THC (Group D).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VER-01 multiple dose (5 mg THC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PK profile is investigated after oral intake of VER-01 corresponding to 5 mg THC in the morning and 5 mg THC in the evening on 4 consecutive days (Group E).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VER-01 multiple dose (10 mg THC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PK profile is investigated after oral intake of VER-01 corresponding to 10 mg THC in the morning and 10 mg THC in the evening on 4 consecutive days (Group F).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VER-01 multiple dose (12.5 / 20 mg THC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PK profile is investigated after oral intake of VER-01 corresponding to 12.5 mg THC in the morning and 20.5 mg THC in the evening on 4 consecutive days (Group F).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VER-01</intervention_name>
    <description>standardised cannabis extract (containing 21 mg THC per gram drug product)</description>
    <arm_group_label>VER-01 multiple dose (10 mg THC)</arm_group_label>
    <arm_group_label>VER-01 multiple dose (12.5 / 20 mg THC)</arm_group_label>
    <arm_group_label>VER-01 multiple dose (5 mg THC)</arm_group_label>
    <arm_group_label>VER-01 single dose (10 mg THC)</arm_group_label>
    <arm_group_label>VER-01 single dose (2.5 mg THC)</arm_group_label>
    <arm_group_label>VER-01 single dose (20 mg THC)</arm_group_label>
    <arm_group_label>VER-01 single dose (5 mg THC)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male volunteers&#xD;
&#xD;
          -  Age: 18-45 years&#xD;
&#xD;
          -  BMI: 19-30 kg/m²&#xD;
&#xD;
          -  Body weight ≥ 50 kg&#xD;
&#xD;
          -  volunteers in good general condition based on medical history, physical examination,&#xD;
             resting ECG and clinical laboratory tests&#xD;
&#xD;
          -  Willingness of men to use a reliable method of contraception and not to donate sperm&#xD;
             during and at least 3 months after the last intake of the study product&#xD;
&#xD;
          -  Understanding of the German language, ability to give consent and compliance&#xD;
&#xD;
          -  The subject has understood the instructions to avoid changes in lifestyle and eating&#xD;
             habits&#xD;
&#xD;
          -  Signed patient information and written informed consent form of the study participant&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Consumption of cannabis-based products within 30 days prior to study start&#xD;
&#xD;
          -  Well-known strong adverse events in connection with cannabis consumption&#xD;
&#xD;
          -  Known allergy to cannabis, sesame seeds, or derivative products&#xD;
&#xD;
          -  alcohol/drug/medication abuse or physical dependence on opioids, barbiturates,&#xD;
             amphetamines, cocaine or benzodiazepines within the last 10 years or current intake of&#xD;
             methadone&#xD;
&#xD;
          -  Positive drug test for illegal substances and/or alcohol test at time T0&#xD;
&#xD;
          -  Heavy smokers (&gt;10 cigarettes/day)&#xD;
&#xD;
          -  Heavy caffeine consumers (&gt;450 mg caffeine/day equal to approx. 5-6 cups of filter&#xD;
             coffee)&#xD;
&#xD;
          -  Drastic change in diet within 30 days before study start&#xD;
&#xD;
          -  Mental illness (psychoses, schizophrenia, bipolar disorder, severe depression, anxiety&#xD;
             disorder, suicide)&#xD;
&#xD;
          -  Mental illness (psychoses, schizophrenia, bipolar disorder, severe depression, anxiety&#xD;
             disorder, suicide) in a first-degree relative (parents and children)&#xD;
&#xD;
          -  subjects with orthostatic hypotension during screening (drop in systolic blood&#xD;
             pressure by ≥20 mmHg after change of position)&#xD;
&#xD;
          -  Cardiovascular event within the last 3 months, untreated hypertension, untreated&#xD;
             hypothyroidism, surgery within the last 2 months&#xD;
&#xD;
          -  cardiac insufficiency&#xD;
&#xD;
          -  Subjects with a serious disease or disorder which, in the opinion of the investigator,&#xD;
             does not allow safe participation in the study from a medical point of view&#xD;
&#xD;
          -  Intake of prescription drugs within the last 14 days, over-the-counter test products&#xD;
             within the last 7 days before the start of the study or during the study period&#xD;
&#xD;
          -  Eating of grapefruit products is not allowed during the study and 10 days before the&#xD;
             first intake of the study product&#xD;
&#xD;
          -  Participation in another clinical trial in the period of 90 days before the start of&#xD;
             the trial&#xD;
&#xD;
          -  Existing desire to have children or planned sperm donation (within the duration of the&#xD;
             study and 3 months after end of the study)&#xD;
&#xD;
          -  Planned blood donation&#xD;
&#xD;
          -  No ability to consent&#xD;
&#xD;
          -  Subject is in a dependency/employment relationship with the sponsor or investigator or&#xD;
             other persons who may be under pressure.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Wolzt, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Medicine in Vienna - Department of Clinical Pharmacology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bastian Baasch</last_name>
    <phone>+4989787979078</phone>
    <email>regulatory@vertanical.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Monika Luca, Dr.</last_name>
    <phone>+4989787979078</phone>
    <email>regulatory@vertanical.com</email>
  </overall_contact_backup>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 24, 2021</study_first_submitted>
  <study_first_submitted_qc>June 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2021</study_first_posted>
  <last_update_submitted>June 17, 2021</last_update_submitted>
  <last_update_submitted_qc>June 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>THC</keyword>
  <keyword>Tetrahydrocannabinol</keyword>
  <keyword>Cannabis</keyword>
  <keyword>Pharmacokinetics</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

